Newsroom | Medtronic | 2019 Press Releases

2019 Press Releases


201920182017201620152014
Search News Releases
 
DateTitle  
02/15/19Medtronic Statement Regarding Revised IN.PACT Post Market Study Data
Medtronic Statement Regarding Revised IN.PACT Post Market Study Data DUBLIN - February 15, 2019 - Medtronic plc (NYSE:MDT) today issued the following statement regarding revised clinical study data: Recently, Medtronic became aware of a programming error in the clinical data reporting isolated to the two- and three-year follow-up periods in our IN.PACT Global post-market study, part of the IN.PACT Admiral clinical program for the treatment of femoropopliteal artery disease. Preliminary results ... 
 Printer Friendly Version
02/14/19Medtronic and Medical University of South Carolina Partner to Improve Patient Outcomes
   Value-Based Health Care Partnership Will Target   Acute Conditions and Chronic Diseases in South CarolinaDUBLIN and CHARLESTON, S.C. - February 14, 2019 - Medtronic plc (NYSE:MDT) and the Medical University of South Carolina (MUSC) today announced a five-year value-based health care partnership intended to transform and improve care for patients in South Carolina. The collaboration will focus on developing solutions that improve the health outcomes and care experiences for pa... 
Download PDFPrinter Friendly Version
02/08/19Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2019
DUBLIN - February 8, 2019 - Medtronic plc (NYSE:MDT) announced today that it will report financial results for the third quarter of fiscal year 2019 on Tuesday, February 19 , 2019. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2019, which ended on Friday, January 25, 2019.Medtronic will host a web... 
Download PDFPrinter Friendly Version
02/07/19Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device
Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain AneurysmsDUBLIN - February 7, 2019 - Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex embolization device.1Previously indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms (IAs) in the interna... 
Download PDFPrinter Friendly Version
01/30/19Medtronic Valiant(TM) Captivia(TM) Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients
New RESCUE Trial Data Presented in Blunt Thoracic Aortic InjuryDUBLIN and SAN DIEGO - January 30, 2019 - Medtronic plc (NYSE:MDT) today announced new data supporting the long-term durability, safety, and efficacy of the Valiant(TM) Captivia(TM) thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department of Cardiac Surgery at The Society of Thoracic Surgeons Annual Meeting, was the first and o... 
Download PDFPrinter Friendly Version
01/30/19Medtronic Announces Positive Results from the Largest ENB Study to Aid in Lung Cancer Diagnosis, Staging, and Treatment Preparation in a Single Minimally Invasive Procedure
Company Is Committed to Leading Evidence Generation Across the Lung Cancer Care ContinuumMedtronic Initiates Separate Study to Evaluate the Safety and Performance of the Emprint(TM) Ablation Catheter with the superDimension(TM) Navigation System for Lung Ablation ProceduresDUBLIN - January 30, 2019 - Medtronic plc (NYSE:MDT) today announced that the Journal of Thoracic Oncology has published 12-month results of the NAVIGATE study, the largest, prospective, multicenter trial evaluating electromag... 
Download PDFPrinter Friendly Version
01/28/19Medtronic Announces U.S. Commercial Launch of Mazor X Stealth(TM) Edition for Robotic-Assisted Spine Surgery
First U.S. Patients Treated Using Mazor X Stealth(TM) Edition at Norton Healthcare and Reston Hospital CenterDUBLIN - January 28, 2019 - Medtronic plc (NYSE:MDT) today announced the first U.S. patients treated with the Mazor X Stealth(TM) Edition for spine surgery following its recent commercial launch. The Mazor X Stealth Edition offers a fully-integrated procedural solution for surgical planning, workflow, execution and confirmation. The system was first used at Norton Healthcare in Louisville... 
Download PDFPrinter Friendly Version
01/24/19Medtronic to Acquire EPIX Therapeutics, Expanding Its Cardiac Ablation Portfolio
(GLOBE NEWSWIRE via COMTEX) --DiamondTemp Ablation System Represents Disruptive RF Innovation DUBLIN - January 24, 2019 - Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement to acquire EPIX Therapeutics, Inc. (EPIX), a privately-held medical device company that designs and manufactures a novel, catheter-based, temperature-controlled cardiac ablation system for the treatment of patients with cardiac arrhythmias (irregular heartbeats), including atrial fibr... 
Download PDFPrinter Friendly Version
01/22/19Patient-Level Survival Analysis Demonstrates No Link Between Paclitaxel Dose and Mortality in Patients Treated with IN.PACT Admiral DCB
Data Presented Today at LINC Reiterate Commitment to Patient Safety and Data TransparencyDUBLIN and LEIPZIG, Germany - January 22, 2019 - Medtronic plc (NYSE:MDT) today announced new data shared on the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries. Outcomes from the IN.PACT DCB Paclitaxel Safety Analysis, an independent, patient-level survival analysis inclusive of all IN.PACT DCB clinica... 
Download PDFPrinter Friendly Version
01/17/19Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery
Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral OpioidsDUBLIN - January 17, 2019 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the SynchroMed(TM) II intrathecal drug delivery system ("Medtronic pain pump") as an alternative to oral opioids for patients with chronic... 
Download PDFPrinter Friendly Version
01/15/19Medtronic Launches Mobile App That Communicates Directly with World's First Smartphone-Connected Pacemakers
MyCareLink Heart(TM) Mobile App Allows Pacemaker Patients to Easily Stay Connected with Their ClinicsDUBLIN - January 15, 2019 - Medtronic plc (NYSE:MDT) today announced the launch of its MyCareLink Heart(TM) mobile app to support the world's first and only portfolio of pacemakers that can communicate directly with patients' smartphones and tablets.Compatible with Medtronic BlueSync(TM) technology-enabled pacemakers, the MyCareLink Heart mobile app is designed to securely and wirelessly send dev... 
Download PDFPrinter Friendly Version
01/09/19Medtronic Foundation Recognizes 12 Bakken Invitation Honorees For Driving Positive Change In Healthcare
Program Celebrates the Legacy of Medtronic Co-Founder Earl Bakken and Other Outstanding Patient Advocates Around the WorldMINNEAPOLIS and Kona, Hawaii - January 9, 2019 - The Medtronic Foundation today announced 12 individuals from around the world as recipients of the 2018 Bakken Invitation. This Medtronic Foundation program recognizes and connects people who "live on, give on and dream on" through their advocacy, contributions to innovation and volunteerism after overcoming health challenges w... 
Download PDFPrinter Friendly Version
01/03/19New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health
Untitled Document IQcast Feature Aims to Predict the Likelihood of a Low Glucose Event Up to Four Hours in AdvanceDUBLIN and CAMBRIDGE, Mass. - January 3, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced a new feature for the Sugar.IQ(TM) personal diabetes assistant app called IQcast(TM). Using artificial intelligence (AI) technology from IBM Wat... 
Download PDFPrinter Friendly Version
X